Labcorp's Alzheimer's Disease Blood Test Cleared by FDA
MT Newswires Live
3 hours ago
Labcorp (LH) said Monday that its blood test that detects Alzheimer's disease is now available after receiving clearance from the US Food and Drug Administration.
The company said its Elecsys pTau-217 test, developed by Roche Diagnostics, helps identify amyloid pathology associated with Alzheimer's disease in people aged 55 and older with signs, symptoms, or complaints of cognitive decline.
The test, according to Labcorp, is the only FDA-cleared single-biomarker blood test to rule in and rule out amyloid pathology in specialty and primary care settings.
Labcorp said it expects the test to be available nationwide in the coming months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.